U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H21FN6O2S
Molecular Weight 488.537
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ILORASERTIB

SMILES

NC1=NC=C(C2=CN(CCO)N=C2)C3=C1C(=CS3)C4=CC=C(NC(=O)NC5=CC(F)=CC=C5)C=C4

InChI

InChIKey=WPHKIQPVPYJNAX-UHFFFAOYSA-N
InChI=1S/C25H21FN6O2S/c26-17-2-1-3-19(10-17)31-25(34)30-18-6-4-15(5-7-18)21-14-35-23-20(12-28-24(27)22(21)23)16-11-29-32(13-16)8-9-33/h1-7,10-14,33H,8-9H2,(H2,27,28)(H2,30,31,34)

HIDE SMILES / InChI

Molecular Formula C25H21FN6O2S
Molecular Weight 488.537
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ilorasertib (previously known as ABT-348), an orally bioavailable ATP-competitive inhibitor of Aurora kinases (A, B and C), as well as the VEGF and PDGF families of receptor tyrosine kinases, was developed by AbbVie as an antineoplastic agent. It is known that Aurora kinases A, B, and C play essential roles in mitotic checkpoint control and are overexpressed by a wide variety of tumor cell types. Both VEGFRs and PDGFRs may be upregulated in various tumor cell types. Ilorasertib alone or in combination with azacitidine demonstrated activity in preclinical models in various hematological malignancies, indicating that pan-Aurora kinase and multiple kinase inhibition may have preferential antileukemic activity. Ilorasertib participated in phase I clinical for patients with advanced hematologic malignancies. The result has shown that the drug could be further studied in acute myelogenous leukemia. Ilorasertib is also going to be studied in phase II clinical trials to learn if this drug can help to control CDKN2A-deficient cancer in patients with advanced cancers.

Approval Year

Sample Use Guides

Part 1 Dose of Ilorasertib: 200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle. Part 2 Expansion: Ilorasertib200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 01:29:28 GMT 2023
Edited
by admin
on Sat Dec 16 01:29:28 GMT 2023
Record UNII
6L5D03D975
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ILORASERTIB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
ILORASERTIB [USAN]
Common Name English
Ilorasertib [WHO-DD]
Common Name English
UREA, N-(4-(4-AMINO-7-(1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-YL)THIENO(3,2-C)PYRIDIN-3-YL)PHENYL)-N'-(3-FLUOROPHENYL)-
Systematic Name English
ABBOTT-968660
Code English
A-968660.0
Code English
N-(4-(4-AMINO-7-(1-(2-HYDROXYETHYL)-1H-PYRAZOL-4-YL)THIENO(3,2-C)PYRIDIN-3-YL(PHENYL)-N'-(3-FLUOROPHENYL)UREA
Common Name English
ilorasertib [INN]
Common Name English
ABT-348
Code English
A-968660
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 364212
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
FDA ORPHAN DRUG 337811
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
NCI_THESAURUS C1404
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID10153718
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY
PUBCHEM
46207586
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY
ChEMBL
CHEMBL1980297
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY
FDA UNII
6L5D03D975
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY
USAN
YY-111
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY
CAS
1227939-82-3
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY
DRUG BANK
DB11694
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY
SMS_ID
100000175009
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY
EU-Orphan Drug
EU/3/12/1001(WITHDRAWN)
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2015 on request of the Sponsor. On 6 June 2012, orphan designation (EU/3/12/1001) was granted by the European Commission to Abbott Laboratories, United Kingdom, for 1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl] thieno [3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea for the treatment of ovarian cancer. The sponsorship was transferred to AbbVie Ltd, United Kingdom, in January 2013.
EU-Orphan Drug
EU/3/11/915(WITHDRAWN)
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2015 on request of the Sponsor. On 27 October 2011, orphan designation (EU/3/11/915) was granted by the European Commission to Abbott Laboratories, United Kingdom, for 1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H- pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-3-(3-fluorophenyl)urea for the treatment of acute myeloid leukaemia. The sponsorship was transferred to AbbVie Ltd, United Kingdom, in January 2013.
NCI_THESAURUS
C116729
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY
INN
9670
Created by admin on Sat Dec 16 01:29:28 GMT 2023 , Edited by admin on Sat Dec 16 01:29:28 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY